Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 164

The DOI matches its Crossref record.

Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).

Traina, Tiffany A., Miller, Kathy, Yardley, Denise A., O'Shaughnessy, Joyce, Cortes, Javier, Awada, Ahmad, Kelly, Catherine Margaret, Trudeau, Maureen E., Schmid, Peter, Gianni, Luca, García-Estevez, Laura, Nanda, Rita, Ademuyiwa, Foluso Olabisi, Chan, Stephen, Steinberg, Joyce Leta, Blaney, Martha Elizabeth, Tudor, Iulia Cristina, Uppal, Hirdesh, Peterson, Amy C., Hudis, Clifford A.·2015·Journal of Clinical Oncology

Abstract

1003 Background: The AR may be a therapeutic target for pts with androgen-driven TNBC. ENZA, a potent AR inhibitor, is approved in men with metastatic castration-resistant prostate cancer (mCRPC) and improves median PFS compared to bicalutamide in men with mCRPC (15.7 vs 5.8 mos; HR 0.44; p<0.0001). Methods: MDV3100-11 was an open-label, Simon 2-stage study evaluating single agent ENZA in advanced AR+ TNBC (AR >0% by IHC; NCT01889238). Pts could be prescreened for AR, and have non-measurable bone disease and unlimited prior regimens; CNS metastases or seizure history were exclusionary. The primary endpoint was clinical benefit (CR, PR or SD) at 16 wks (CBR16) in ‘Evaluable’ pts defined as having both AR IHC ≥10% and a response assessment. CBR24, PFS, response rate, and safety were assessed. An androgen-driven gene signature (Dx) was created from gene profiling and outcomes were assessed accordingly. Stage 2 enrolled if CBR16 was ≥3 of 26 Evaluable pts; H0 was rejected if CBR16 was ≥9 in 62 yielding 85% power at 5% significance to test against a 1-sided alternative (CBR16 ≥20%). Results: As of 16 JAN 2015, 404 samples were tested for AR IHC: 79% had AR >0%; 55% had AR ≥10%. 118 pts were treated with ENZA; 43 pts were not Evaluable (29 AR <10%; 14 AR ≥10% but no response assessment). Key outcomes in the defined populations are below as shown in the Table. Over 50% received ENZA as 1st or 2nd line; mPFS in these pts was 32 wks in Dx+ and 9 wks in Dx-. Two CRs and 5 PRs have been observed. Related AEs in ≥10% of 118 pts were fatigue (34%), nausea (25%), decreased appetite (13%), diarrhea and hot flush (10%). Fatigue (5%) was the only AE ≥ Grade 3 in ≥5%. Conclusions: This is the largest study of an AR inhibitor in TNBC. IHC results suggest AR prevalence is higher than previously reported. 47% of pts had an androgen-related gene signature (Dx+) and clinical outcomes appeared superior in this group. AEs from ENZA were consistent with its known profile. ENZA may represent a novel therapeutic option in pts with TNBC who would otherwise receive cytotoxic chemotherapy. Clinical trial information: NCT01889238. Evaluable n=75 Dx+ n=56 Dx- n=62 CBR16, % (95% CI) 35 (24-46) 39 (27-53) 11 (5-21) CBR24, % (95% CI) 29 (20-41) 36 (24-49) 7 (2-16) mPFS, wks (95% CI) 14 (8-19) 16 (10-32) 8 (7-13)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.33.15_suppl.1003

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 164

Metadata

Authors
Traina, T. A., Miller, K., Yardley, D. A., O'Shaughnessy, J., Cortes, J., Awada, A., Kelly, C. M., Trudeau, M. E., Schmid, P., Gianni, L., García-Estevez, L., Nanda, R., Ademuyiwa, F. O., Chan, S., Steinberg, J. L., Blaney, M. E., Tudor, I. C., Uppal, H., Peterson, A. C., & Hudis, C. A.
Venue
Journal of Clinical Oncology
Published
2015-05-20
Volume
33
Issue
15_suppl
Pages
1003-1003
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2471690942
Cited by
164
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). https://app.cochat.ai/papers/10.1200/jco.2015.33.15_suppl.1003
The paper
Traina, T. A., Miller, K., Yardley, D. A., O'Shaughnessy, J., Cortes, J., Awada, A., Kelly, C. M., Trudeau, M. E., Schmid, P., Gianni, L., García-Estevez, L., Nanda, R., Ademuyiwa, F. O., Chan, S., Steinberg, J. L., Blaney, M. E., Tudor, I. C., Uppal, H., Peterson, A. C., & Hudis, C. A. (2015). Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.33.15_suppl.1003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.